Deucravacitinib is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Limitations of Use:
Deucravacitinib is not recommended for use in combination with other potent immunosuppressants.
from FDA,2022.09